Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ABL1 | P00519 | 20/20 | 1.00 |
| ▸ | BCR | P11274 | 18/20 | 1.00 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.72 |
| ▸ | MAPT | P10636 | 1/20 | 0.72 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.72 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL924071 | 1.00 | ABL1 (1.00) | ABL1BCRKDM4EMAPTMAPK1 | |
| SCHEMBL25735738 | 0.93 | ABL1 (0.86) | ABL1BCRKDM4EMAPTMAPK1 | |
| SCHEMBL25824263 | 0.90 | ABL1 (0.82) | ABL1BCRKDM4EMAPTMAPK1 | |
| SCHEMBL3902519 | 0.89 | ABL1 (0.80) | ABL1BCRKDM4EMAPTMAPK1 | |
| SCHEMBL16898587 | 0.88 | ABL1 (0.79) | ABL1BCRKDM4EMAPTMAPK1 | |
| SCHEMBL16898190 | 0.88 | ABL1 (0.78) | ABL1BCRKDM4EMAPTMAPK1 | |
| SCHEMBL16898602 | 0.88 | ABL1 (0.78) | ABL1BCRKDM4EMAPTMAPK1 | |
| SCHEMBL16898654 | 0.88 | ABL1 (0.78) | ABL1BCRKDM4EMAPTMAPK1 | |
| SCHEMBL16898548 | 0.87 | ABL1 (0.77) | ABL1BCRKDM4EMAPTMAPK1 | |
| SCHEMBL16898299 | 0.87 | ABL1 (0.77) | ABL1BCRKDM4EMAPTMAPK1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 90 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12419891-B2 | Compositions for the treatment of pathogenic- and/or chemical-induced lung injury and for the treatment of cancer and methods of using same | DUKE UNIVERSITY (US) | 2025-09-23 | — | — | US | claimed |
| WO-2025007166-A1 | BCR-ABL INHIBITORS FOR USE IN TREATING KELOID DISEASE | UNIVERSITY OF CAPE TOWN (ZA) | 2025-01-02 | — | — | WO | claimed |
| US-20240390370-A1 | Compositions for the Treatment of Pathogenic- And/Or Chemical-Induced Lung Injury and for the Treatment of Cancer and Methods of Using Same | DUKE UNIVERSITY | 2024-11-28 | — | — | US | claimed |
| US-12104168-B2 | Cell culture medium | AGENCY FOR SCIENCE, TECHNOLOGY AND RESEARCH (A*STAR) (SG) | 2024-10-01 | — | — | US | claimed |
| US-20240156816-A1 | METHODS AND COMPOSITIONS FOR PREDICTING AND PREVENTING RELAPSE OF ACUTE LYMPHOBLASTIC LEUKEMIA | DANA-FARBER CANCER INSTITUTE, INC. | 2024-05-16 | — | — | US | claimed |
| CN-113786409-B | Compositions comprising phosphoinositide 3-kinase inhibitors and a second antiproliferative agent | 甫康（上海）健康科技有限责任公司 | 2024-04-02 | — | — | CN | claimed |
| US-20240058335-A1 | METHODS FOR TREATMENT OF CANCER USING ABL INHIBITORS AND DRUGS TARGETING THE MEVALONATE PATHWAY | DUKE UNIVERSITY (US) | 2024-02-22 | — | — | US | claimed |
| US-11883401-B2 | Compositions for the treatment of pathogenic- and/or chemical-induced lung injury and for the treatment of cancer and methods of using same | DUKE UNIVERSITY (US) | 2024-01-30 | — | — | US | claimed |
| US-11844800-B2 | Methods and compositions for predicting and preventing relapse of acute lymphoblastic leukemia | MASSACHUSETTS INSTITUTE OF TECHNOLOGY (US) | 2023-12-19 | — | — | US | claimed |
| EP-3337477-B1 | COMPOSITIONS COMPRISING PHOSPHOINOSITIDE 3-KINASE INHIBITORS AND A SECOND ANTIPROLIFERATIVE AGENT | CONVALIFE SHANGHAI CO LTD (CN) | 2023-02-01 | — | — | EP | claimed |
| US-20260109694-A1 | HETEROCYCLIC COMPOUNDS AND USES THEREOF | KUMQUAT BIOSCIENCES INC (US) | 2026-04-23 | — | — | US | disclosed |
| EP-4720059-A1 | HETEROCYCLIC COMPOUNDS AND USES THEREOF | Kumquat Biosciences Inc. (US) | 2026-04-08 | — | — | EP | disclosed |
| US-12551555-B2 | Compositions and methods for potentiating immune activity | KUMQUAT BIOSCIENCES INC. (US) | 2026-02-17 | — | — | US | disclosed |
| US-12503464-B2 | 1,2,5-thiadiazolidin-3-one 1,1-dioxide containing compounds and uses thereof | KUMQUAT BIOSCIENCES INC. (US) | 2025-12-23 | — | — | US | disclosed |
| EP-4658317-A1 | PROGRAMMABLE DNA PROTEOLYSIS TARGET CHIMERAS AND METHODS OF THEIR USE | Arizona Board of Regents on behalf of Arizona State University (US) | 2025-12-10 | — | — | EP | disclosed |
| WO-2022165185-A1 | CANCER-SELECTIVE TARGET DEGRADATION BY TARGETING GROUP CAGED PROTACS | BETH ISRAEL DEACONESS MEDICAL CENTER, INC. (US) | 2022-08-04 | — | — | WO | disclosed |
| US-20220170109-A1 | PURITY INDEPENDENT SUBTYPING OF TUMORS (PURIST), A PLATFORM AND SAMPLE TYPE INDEPENDENT SINGLE SAMPLE CLASSIFIER FOR TREATMENT DECISION MAKING IN PANCREATIC CANCER | THE UNIVERSITY OF NORTH CAROLINA AT CHAPEL HILL (US) | 2022-06-02 | — | — | US | disclosed |
| US-11324827-B2 | Multifunctionalized polyethylene glycol derivative and preparation method therefor | XIAMEN SINOPEG BIOTECH CO., LTD. (CN) | 2022-05-10 | — | — | US | disclosed |
| US-11291669-B2 | Compositions comprising phosphoinositide 3-kinase inhibitors and a second antiproliferative agent | KARUS THERAPEUTICS LIMITED (GB) | 2022-04-05 | — | — | US | disclosed |
| CN-108379591-B | Synthesis of immune agonist targeting compound and application thereof | 深圳大学 | 2022-03-29 | — | — | CN | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (9 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11883401-B2 | Compositions for the treatment of pathogenic- and/or chemical-induced lung injury and for the treatment of cancer and methods of using same | DDIT3, MCL1, MYD88 | ABL1 938/4885BCR 445/4885KDM4E 4383/4885 |
| US-20260109694-A1 | HETEROCYCLIC COMPOUNDS AND USES THEREOF | CCR10, SLC11A2, MSR1 | ABL1 3589/4885BCR 417/4885KDM4E 4595/4885 |
| US-20240058335-A1 | METHODS FOR TREATMENT OF CANCER USING ABL INHIBITORS AND DRUGS TARGETING THE MEVALONATE PATHWAY | ABL2, ABL1, VAV1 | ABL1 2/4885BCR 6/4885KDM4E 996/4885 |
| US-12551555-B2 | Compositions and methods for potentiating immune activity | PTPRCAP, PTPN2, PTPRC | ABL1 296/4885BCR 59/4885KDM4E 2917/4885 |
| US-20240390370-A1 | Compositions for the Treatment of Pathogenic- And/Or Chemical-Induced Lung Injury and for the Treatment of Cancer and Methods of Using Same | DDIT3, MCL1, MYD88 | ABL1 938/4885BCR 445/4885KDM4E 4383/4885 |
| US-12503464-B2 | 1,2,5-thiadiazolidin-3-one 1,1-dioxide containing compounds and uses thereof | BRCA1, STING1, IFNG | ABL1 539/4885BCR 1890/4885KDM4E 2812/4885 |
| US-11291669-B2 | Compositions comprising phosphoinositide 3-kinase inhibitors and a second antiproliferative agent | MCL1, MYC, XIAP | ABL1 913/4885BCR 510/4885KDM4E 1556/4885 |
| US-12419891-B2 | Compositions for the treatment of pathogenic- and/or chemical-induced lung injury and for the treatment of cancer and methods of using same | DDIT3, MCL1, MYD88 | ABL1 938/4885BCR 445/4885KDM4E 4383/4885 |
| US-11324827-B2 | Multifunctionalized polyethylene glycol derivative and preparation method therefor | HDGF, F11, F12 | ABL1 3984/4885BCR 1671/4885KDM4E 4115/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.